FINWIRES · TerminalLIVE
FINWIRES

Sunshine Lake Pharma Wins China Marketing Approval for Insulin Degludec

By

Sunshine Lake Pharma (HKG:6887) posted that China's National Medical Products Administration approved the marketing of its Insulin Degludec Injection, according to a Thursday Hong Kong bourse filing.

The long-acting basal insulin, developed in-house, received approval in both cartridge and prefilled pen formats.

The company said the once-daily treatment provides blood glucose control for more than 42 hours and offers greater dosing flexibility.

Related Articles